News

Crinetics Pharmaceuticals Grants New Employee Stock Options

Crinetics Pharmaceuticals Grants New Employee Stock Options

Crinetics Pharmaceuticals Executes New Employee Stock Awards

The innovative team at Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, has recently taken an exciting step in enhancing its workforce by issuing stock options and restricted stock units (RSUs) to new employees. This announcement arrives with the intent to foster talent acquisition and offer material inducement to prospective employees, adhering to Nasdaq's guidelines.

The Inducement Grant Overview

On a recent date in March 2025, the Compensation Committee of the company’s Board of Directors took substantial action by granting non-qualified stock option awards that could lead to the purchase of a total of 95,675 shares designated for 15 new non-executive employees. In a significant move, an additional 80,000 shares were allocated to welcome one new executive employee. Alongside these options, the committee also awarded 40,775 RSUs to sixteen non-executives and a separate allotment of 52,000 RSUs for one new executive. These equity awards were all granted under the Crinetics Pharmaceuticals 2021 Employment Inducement Incentive Award Plan.

Understanding the 2021 Inducement Plan

The 2021 Inducement Plan plays a crucial role in Crinetics’ strategy for recruiting new talent, specifically targeting individuals who are entering the company for the first time or following a break in employment. This initiative is designed to align employees' interests with the company's success, which ultimately enhances employee engagement and retention. The stock options granted carry an exercise price of $33.75 per share, equating to the market closing price of the company’s stock on the execution date.

Vesting Details

For those lucky enough to receive stock options, the benefits will not be immediate. The shares are set to vest over a period of four years, with the first 25% becoming available only after the first year of employment. Following this, the remaining shares will vest in 36 equal monthly installments, making continued employment essential for the full benefit of these awards. Similarly, the RSUs will also vest in equal amounts annually over four years following the first anniversary of their grant, emphasizing the long-term relationship Crinetics aims to build with its employees.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals prides itself as a dynamic clinical-stage pharmaceutical entity that concentrates on developing innovative therapies for various endocrine disorders and related tumors. One of the company’s hallmark products is paltusotine, which is pioneering as a once-daily oral selective somatostatin receptor type 2 (SST2) nonpeptide agonist. This therapeutic candidate is in advanced stages of clinical development targeting conditions like acromegaly and carcinoid syndrome occurring alongside neuroendocrine tumors. Furthermore, Crinetics is actively engaged in the development of another promising investigational agent, atumelnant, the first oral ACTH antagonist aimed at conditions like congenital adrenal hyperplasia and Cushing’s disease. The company is steadfast in its mission to discover and deliver novel small-molecule medications that can aid in addressing numerous endocrine-related health concerns, including hyperparathyroidism, obesity, and various oncological indications.

Contact Information

Crinetics Pharmaceuticals continues to maintain open lines of communication with stakeholders. Investors can reach out to Gayathri Diwakar, the Head of Investor Relations, at their official email, and they can also contact her directly at (858) 345-6340 for any inquiries regarding the company's stock or investment opportunities.

For media relations, Natalie Badillo serves as the Head of Corporate Communications and is available at (858) 450-6464 for press inquiries and communications.

Frequently Asked Questions

What are the recent inducement grants by Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals granted stock options and RSUs to new non-executive and executive employees as part of its inducement plans to attract talent.

How long will the stock options vest?

The stock options will vest over four years, with 25% vesting at the one-year mark, followed by monthly increments thereafter.

What is the purpose of the 2021 Inducement Plan?

The plan is designed to provide equity awards to new employees as an inducement to accept job offers and align their interests with the company’s performance.

Which key compounds are in development by Crinetics Pharmaceuticals?

Paltusotine and atumelnant are two key investigational compounds focusing on endocrine disorders and conditions like Cushing’s disease.

Who can I contact for investor relations with Crinetics?

Gayathri Diwakar is the Head of Investor Relations and can be contacted at her official email for inquiries regarding investments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

iHeartMedia Faces 65% Drop: Fraud Investigation Launched

Updated Category News Views 150

Trouble Tunes for iHeartMedia Investors Alright folks, here's the skinny on iHeartMedia, Inc. These days, it's like everyone's out for a piece of iHeart, and not in the way you'd wanna see—unless you're SBS Law, those shareholder rights hotshots diving into another pond of legal ripples. Seems a heap of head-scratching's going down on their version of transparency with...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 49

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 106

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 208

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 155

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
NEDHSA Amplifies Tobacco-Free Push with 2026 Smokeout

Updated Category News Views 87

2026 Great American Smokeout: A Fresh Push Against Tobacco NEDHSA is sticking to its guns with a tobacco-free campaign that’s got deep roots. The 2026 Great American Smokeout, on November 19, not only highlights past efforts but looks to stir more folks into healthier habits. Beyond the campaign glitz, it’s about dragging a century-long bad habit further into the...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 327

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 172

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 0

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading

Top 5 Most Recently Viewed Articles

Epson Robots Unveils Cutting-Edge Automation Tech at Expo

Updated Category News Views 360

Innovative Automation Solutions by Epson Robots Epson Robots is set to showcase its latest high-performance automation solutions at an upcoming major tradeshow. The focus will be on the exciting advancements in the SCARA and 6-Axis robots, which are recognized globally for their efficiency and precision in various industries. Exciting New Product Launches At the event,...

Continue Reading
Rexel Reports Fourth Quarter Growth Amid Market Challenges

Updated Category News Views 313

Rexel's Financial Performance Overview Rexel has released its fourth quarter (Q4) and full year (FY) financial results, showcasing strong performance amid challenging market conditions. The company's FY 2024 sales reached €19,285.1 million, reflecting a modest year-on-year increase of 0.7% on a reported basis. This growth narrative underscores Rexel's effective...

Continue Reading
Monster Beverage Sees Gains in 2025 First Quarter Results

Updated Category News Views 313

Monster Beverage's Impressive First Quarter Growth 2025 First Quarter Highlights The financial landscape for Monster Beverage Corporation (NASDAQ: MNST) revealed compelling growth in the first quarter of 2025. Gross profit as a percentage of net sales improved significantly, reaching 56.5 percent. The company reported an operating income increase of 5.1 percent, totaling...

Continue Reading
Transforming Metastatic HR+/HER2- Breast Cancer Care Innovations

Updated Category News Views 215

Transforming Treatment Strategies for Metastatic HR+/HER2- Breast Cancer In recent years, the landscape of metastatic HR+/HER2- breast cancer treatment has evolved dramatically. With innovative therapies coming to the forefront, patients now have access to a wider range of treatment options that aim to improve survival rates and quality of life. The rise of targeted...

Continue Reading
Oil Price Surge Driven by Manufacturing Growth in China

Updated Category News Views 193

Understanding the Recent Trends in Oil Prices Oil prices experienced an uptick recently, driven by promising signs from China's manufacturing sector. Reports reveal that China's factory activity demonstrated growth in December, marking it as a significant development in the global oil landscape. However, despite this positive news, oil prices are on a trajectory to finish...

Continue Reading